CCAAT增强子结合蛋白β在胃癌中的表达及其临床意义

目的 探讨CCAAT增强子结合蛋白β(CEBPB)在胃癌组织中的表达及其与胃癌临床病理参数及预后的关系.方法 用免疫组织化学染色方法对81例胃癌组织及其配对癌旁黏膜组织中CEBPB蛋白的表达进行检测,并分析其表达与胃癌临床病理特征及预后的关系.结果 CEBPB蛋白主要定位于细胞核,在胃癌组织中表达阳性率为16％(13/81),癌旁组织中无表达或弱表达.单因素分析显示,CEBPB阳性表达与胃癌远处转移有关(P=0.048).CEBPB阳性表达患者中位生存期19.4个月,低于CEBPB阴性表达患者的45.2个月(P=0.024).多因素分析显示,CEBPB阳性表达是影响本组胃癌患者的独立预后因素(HR=2.544,95％CI:1.154～5.610,P=0.021).结论 CEBPB在胃癌组织中表达增高提示预后不良.

Expression of CCAAT/enhancer binding protein beta in human gastric carcinoma and its clinical significance

Objective To explore the expression of CCAAT/enhaneer binding protein beta （CEBPB）in gastric carcinoma tissues and its association with clinicopathological features and prognosis. Methods CEBPB protein expression level was detected by immunohistochemistry method in resected gastric carcinomas and adjacent gastric mucosa tissues（n=81 ）, and its association with clinieopathologieal features and prognosis was analyzed. Results The immunohistoehemieal staining of CEBPB was predominantly in the nucleus with some cytoplasmic staining. As a result, 16%（13/81） of the gastric carcinomas were stained positively, whereas there was hardly positive expression in adjacent gastric mucosa tissues. There was a significant association between the expression of CEBPB and distant metastasis on univariate analysis （P〈0.05）. The median survival time in patients with positive CEBPB expression was significantly lower than those with negative CEBPB expression （19.4 months vs. 45.2 months, P=0.024）. Muhivariable analysis showed that CEBPB was independently associated with prognosis（HR=2.544, 95%CI：1.154-5.610, P=0.021）. Conclusion Up-regulation of CEBPB suggests poor prognosis in patients with gastric cancer.